Citations

Clear

922 citation(s) found for "He, Jun".

Introducing an innovative IMPT algorithm toward clinic implementation of the MCF MKM RBE model for carbon ion therapy
Tong, Jindong, Liu, Hongcheng , Parisi, Alessio, Han, Dong , Yaddanapudi, Sridhar , Park, Chunjoo, Tan, Jun , Parisi, Alessio , Furutani, Keith, Parisi, Alessio , Yaddanapudi, Sridhar , Tong, Jindong, Parisi, Alessio, Yang, Yu , Liang, Xiaoying , Furutani, Keith M. , Beltran, Chris , Lu, Bo

Mayo Clinic

Medical Physics | November 21, 2025 | Volume: 52 | Issue: 12 | Pages: No page available

10.1002/mp.70148 | PMID 41267206 Get It

Abstract Purpose This study investigates a novel optimization framework that integrates the newly developed MCF MKM relative biological effectiveness (RBE) model into intensity modulated particle therapy (IMPT) planning for carbon ion therapy. Unlike conventional RBE models such as MKM or LEM, the MCF MKM provides detailed microdosimetric information, which improves predictive accuracy of cell survival but elevates both memory and time requirement in the optimization process. Furthermore, to the implicit nature of the MCF MKM, the gradient information, which is essential in inverse planning, is hardly accessible. In response, a randomized gradient‐free optimization method (RGFM) was developed to mitigate the computational challenge and achieve improved RBE dose distributions. Materials and Methods An RBE dose optimization problem was formulated based on the discretized MCF MKM, known as the Abridged Microdosimetry Distribution Model (AMDM). The RGFM was derived to find feasible and high‐quality settings of monitor unit for IMPT plans without the need for explicit gradient calculations. To verify the clinical plausibility of the proposed method, it was tested on two clinical scenarios—prostate and brain cases in comparison with benchmark plans derived solely from physical dose optimization. Computational times and dose‐volume histograms (DVHs) for both physical and RBE doses were evaluated. Results The RGFM algorithm successfully optimized the MCF MKM‐based IMPT plans. Compared to the benchmark, the RBE dose distributions showed improved coverage of the target and reduced hot spots. Such improvements were observed to coincide with trade‐offs in physical dose distributions. The complexity of the MCF MKM extended the computational time, yet high‐quality solutions were attainable in a clinically reasonable timeframe. Multi‐field optimization (MFO) further enhanced target coverage and critical organ sparing over single‐field optimization (SFO). Conclusions This proof‐of‐principle study confirmed the feasibility of using a randomized gradient‐free method to optimize RBE dose based on the MCF MKM in IMPT planning for carbon ion therapy. The approach provides a pathway for clinical adoption of advanced RBE models, potentially leading to more biologically informed and effective carbon ion therapy treatments. Future work involves refining algorithms, incorporating parallel computing, and performing additional case studies to improve computational efficiency and generalizability.
Deficiency of Hv1 Proton Channel Enhances Macrophage Antigen Presentation and Anti-Tumor Responses in Glioma 4365
Zheng, Jiaying, Wang, Lingxiao , Wan, Yushan , Johnson, Aaron J. , Wu, Long‐Jun , Wu, Long-Jun , Zhao, Shunyi , Ayasoufi, Katayoun , Goddery, Emma N. , Strege, Peter R. , Zhang, Wenjing, Xie, Manling , Beyder, Arthur , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.2059 Get It

Abstract Description In the tumor microenvironment of glioblastoma, myeloid cells act as a double-edged sword—they are a major cellular component suppressing the immune response while serving as a promising therapeutic target. Our study sheds light on the voltage-gated proton channel Hv1, predominantly expressed in myeloid cells, as a pivotal regulator of their physiological functions. Elevated Hv1 expression correlates strongly with poor prognosis in glioblastoma patients, underscoring its clinical significance. Using a glioma mouse model, we demonstrated that Hv1 depletion markedly extended survival. To overcome the limitations of existing tools, we engineered novel transgenic mouse lines optimized for Hv1 research. Our findings revealed tumor-induced Hv1 upregulation, with glioma-associated macrophages identified as the principal contributors. Crucially, we identified that Hv1 in infiltrating macrophages as the major driver of survival phenotype differences. Through a multi-faceted approach combining in vivo two-photon imaging, spectral flow cytometry, and spatial transcriptomic sequencing, we discovered that Hv1 depletion limits macrophage infiltration and enhances antigen presentation, ultimately fostering a stronger adaptive immune response. These findings establish the Hv1 channel as a crucial new immune regulator within the brain tumor milieu, offering a promising target for reprogramming macrophage function to combat glioblastoma. Funding Sources Supported by NIH R35NS132326 (LJW); Mayo Clinic Cancer Center and Mayo Clinic Center for Biomedical Discovery. Topic Categories Neuroimmunology (NEUR)
An automated daily QA strategy for dosimetry and imaging guidance check of a novel PET/CT ring gantry linac
Ghimire, Sagar, Park, Yang Kyun, Gibbard, Grant, Tan, Jun , Banks, T. , Shen, Chenyang , Zhuang, Tingliang , Godley, Andrew , Banks, Thomas I , Prasad, Rameshwar , Jiang, Steve B , Cai, Bin, Tan, Jun

Mayo Clinic

Journal of Applied Clinical Medical Physics | November 19, 2025 | Volume: 26 | Issue: 12 | Pages: No page available

10.1002/acm2.70309 | PMID 41253712 Get It

Abstract Background The RefleXion X1 is a novel PET/CT‐guided ring gantry linac that introduces unique geometry and workflow compared to conventional systems. Existing QA guidelines (AAPM TG‐142, 148, 306) cover standard linacs and tomotherapy but do not address this platform's needs. Therefore, an automated daily QA solution is required to ensure accurate output, imaging guidance, and couch positioning, which motivated the development and evaluation of the workflow presented in this study. Purpose To develop and evaluate an automated, efficient, and comprehensive daily quality assurance (QA) workflow for a novel PET/CT‐guided ring gantry linear accelerator (RefleXion X1), incorporating tests for dosimetry, imaging guidance, and couch positioning accuracy. Methods An IMRT QA plan was designed following the CT scan of the TomoDose 2D diode detector array (Sun Nuclear, Melbourne, FL) within the RefleXion treatment planning system (TPS). Several spherical targets of varying sizes were contoured to conform the dose distribution to these targets and evaluate beam output, laser localization, profile constancy, and CT‐MV isocenter coincidence. Linear models correlating spatial location of dose peak with intentional shifts in different directions were developed and integrated into an in‐house analysis software, iQA, written in C#. The software was validated for robustness and successfully implemented in clinical practice. Results Validation with 42 intentional shifts showed submillimeter accuracy, with mean deviations of 0.2 mm (X), 0.1 mm (Y), and 0.79 mm (Z), and R 2 values ≥ 0.98. Over 1 year, daily QA data showed stable output constancy (1.006 ± 0.016), left/right target dose constancy (1.007 ± 0.005 and 0.996 ± 0.004), and consistent CT‐MV isocenter offsets (–0.335 ± 0.23 mm in X, 0.19 ± 0.19 mm in Y, and –0.544 ± 0.36 mm in Z). The software also detected a gradual output drift in between, prompting a timely linac adjustment. Conclusion This fully automated, single‐delivery QA workflow enables efficient and robust evaluation of multiple IGRT performance parameters. It improves standardization, reduces human error, and reliably monitors long‐term machine stability. The tools and methodology may be adopted by other clinics seeking a practical and automated daily QA solution. Future developments will focus on incorporating PET QA and rotational couch validations to further enhance the system's comprehensiveness and adaptability.
Smart Catheters for Diagnosis, Monitoring, and Therapy
Tarman, Azra Yaprak , Ahmed, Samiha , Althumayri, Majed , Guy, Megan, Lugo, Darlenne Chavez, Ligler, Frances S. , Ligler, George T. , Öklü, Rahmi , Bova, Jonathan , Koydemir, Hatice Ceylan , Althumayri, Majed Othman , Kameoka, Jun , Bova, Jonathan , Ceylan Koydemir, Hatice , Oklu, Rahmi , Guy, Megan, Kawahira, Hiroshi , McShane, Michael J.

Mayo Clinic

Advanced Healthcare Materials | November 17, 2025 | Volume: 15 | Issue: 13 | Pages: No page available

10.1002/adhm.202503913 | PMID 41243621 Get It

Abstract This review explores smart catheters as an emerging class of medical devices that combine embedded sensors, robotics, and communication systems with increasing functionality and complexity to enable real‐time health monitoring, diagnostics, and treatment. Evolving from traditional catheters used as drains or entry ports, smart systems are now able to track blood pressure, temperature, biochemical signals, and mechanical forces within the body with a high degree of accuracy. Advances in materials, wireless communication, and robotic navigation have helped reduce common risks like infection and catheter blockage while also improving precision catheter placement for minimally invasive procedures. This review highlights recent developments across a variety of different types of smart catheters, ranging from sensing and imaging tools to therapeutic and multimodal systems. Additionally, it discusses the challenges that remain, including biocompatibility, long‐term performance, and clinical translation. The incorporation of new capabilities is changing how catheters are used, and these new uses promise to enable more personalized and responsive healthcare.
The not-so-shortcomings of seated saline suppression testing in primary aldosteronism
Stowasser, Michael , Eisenhofer, Graeme , Schlaich, Markus P. , Bell, Damon A. , Yang, Jun , Mulatero, Paolo , Young, William F., Williams, Tracy Ann , Reincke, Martín , Yang, Jun , Mulatero, Paolo , Williams, Tracy Ann , Reincke, Martin , Stowasser, Michael , Horvath, Andrea R.

Mayo Clinic

European Journal of Endocrinology | November 14, 2025 | Volume: 193 | Issue: 6 | Pages: L36-L37

10.1093/ejendo/lvaf232 | PMID 41251236 Get It

TMOD-42. TREM2 modulates glioma-associated microglia and macrophage function in a genetic driver dependent manner
Peshoff, Mekenzie , Fei, Mengdi, Pallegar, Praveen N., Wu, Long‐Jun , Wu, Long-Jun , Zheng, Jiaying , Fei, Mengdi, Lu, Qing Richard

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v483-v483

10.1093/neuonc/noaf201.1915 Get It

Abstract Triggering receptor expressed on myeloid cells 2 (TREM2) is a critical modulator of phagocytosis, inflammation, and survival for microglia and other macrophages. In neurodegenerative disorders, microglia expressing TREM2 play a protective role at distinct phases of disease progression, enabling uptake of toxic protein aggregates and dead neurons. TREM2 is also highly expressed on tumor-associated macrophages in a variety of cancers, promoting an immunosuppressive microenvironment. We and others have previously investigated the role of TREM2 in gliomas with confounding results, suggesting TREM2 could be pro-tumorigenic or anti-tumorigenic depending on experimental context (Peshoff, et al. Neuro Oncol. and Zheng, et al. Neuro Oncol.) In this study, we aim to resolve these findings by investigating the role of TREM2 across progression of gliomas with unique genetic drivers using immunocompetent mouse models. We employ syngeneic glioma stem cell lines generated via retroviral vectors expressing a dominant negative p53 along with amplification of human PDGFB or oncogenic HRAS G12V to model proneural and mesenchymal glioblastomas, respectfully. In contrast to our previous results demonstrating enhanced GL261 and CT2A growth in Trem2-/- mice, we demonstrate that Trem2 deficiency results in decreased tumor volume and improved survival when mice are challenged with Ras-driven, but not PDGFB-driven, gliomas. Furthermore, Trem2-/- mice display a more immunostimulatory microenvironment with increased T cell infiltration to mesenchymal-like tumors. We employ an in vitro co-culture system of primary mouse microglia with glioma stem cells to understand how microglia sense and respond to different genetic subtypes. We find that TREM2-mediated processes including microglial phagocytosis, chemotaxis, and survival are impacted by glioma genetic drivers. Together, these results indicate discrepancies in the literature regarding the function of TREM2 in gliomas may be explained by tumor genetics behind the cell lines used, which can provide a framework for understanding subtypes of gliomas that could respond to TREM2-modulating therapy.
IMMU-17. Vessel-Associated Microglia Maintain Vascular Integrity and Prevent Early Hemorrhage in Glioblastoma
Fei, Mengdi, Maynes, Mark Andrew, Peshoff, Mekenzie , Johnson, Aaron J. , Wu, Long‐Jun , Wu, Long-Jun , Zheng, Jiaying , Fei, Mengdi, Maynes, Mark A , Johnson, Aaron J

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v206-v206

10.1093/neuonc/noaf201.0816 Get It

Abstract Aberrant vasculature is a hallmark of glioblastoma (GBM), contributing to both blood–brain barrier (BBB) dysfunction and frequent intracranial hemorrhage. Myeloid cells, including microglia and macrophages, are known to co-opt tumor vasculature during tumor progression, but the nature and consequences of their physical interactions with blood vessels require clearer definition. To address this, we characterize vessel-associated myeloid cells in murine gliomas with high spatial and temporal resolution, leveraging in vivo two-photon imaging, MRI, and transgenic mouse lines. To investigate the role of microglia in glioma vasculature, we pretreated glioma-bearing mice with CSF1R inhibitors (PLX3397 & PLX5622) to ablate microglia prior to tumor inoculation. Strikingly, over half of the microglia-depleted mice developed acute, lethal paralysis between days 11–15, whereas control tumor-bearing mice remained asymptomatic. MRI revealed extensive intracranial hemorrhage and edema, and two-photon imaging showed nodular, abnormal vasculature. This vascular dysfunction led to a dramatic reduction in median survival—from 30 days in control glioma-bearing mice to 15 days in PLX-treated mice with gliomas. To identify the protective microglial population involved, we examined vascular–myeloid interactions. We found that the peritumoral region harbored dense capillary networks supporting tumor expansion, along with a marked increase in myeloid cells with somas directly contacting blood vessels. Using TMEM119CreER/+:R26tdTomato/+ mice, we confirmed these vessel-associated cells as brain-resident microglia, not infiltrating macrophages. Quantitatively, ~60% of peritumoral microglia were vessel-associated, compared to ~30% in naïve or contralateral hemispheres. These microglia displayed elongated somata and processes aligned with vessels or wrapping around vessels, which is a phenotype also observed following single-vessel photothrombosis, suggesting a response to impaired blood flow and BBB leakage. Our findings uncover a critical neurovascular role for vessel-associated microglia in maintaining vascular integrity during glioma progression and highlight the importance of preserving, reprogramming, and further investigating this population in GBM therapies.
MOTS-c Pretreatment Ameliorates the Cardioprotective Effects of Mesenchymal Stem/Stromal Cells Harvested from Patients with Obesity
Yoon, Se-Hee , Lü, Bo , Li, Xing , Zhu, Xiang, Lerman, Amir, Lerman, Lilach O. , Zhang, Lei , Tang, Hui Jun , Kumagai, Hiroshi , Miller, Brendan , Eirin, Alfonso , Lerman, Amir , Cohen, Pinchas

Mayo Clinic

Journal of the American Society of Nephrology | November 10, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.20257sdt3xp9 Get It

SMARTER Education for a Global Transplant Workforce
Esquivel, Carlos O. , Smith, Sydney , Bajpai, Ruhaan, Johnson, Jonathan N. , McCulloch, Mignon , Oh, Jun, Pape, Lars, Bonham, Clark A. , Bartosh, Sharon , Marks, Stephen D. , Twombley, Katherine , Raina, Rupesh , Johnson, Jonathan , Bartosh, Sharon , Twombley, Katherine E , McCulloch, Mignon , Bajpai, Ruhaan

Mayo Clinic

Pediatric Transplantation | November 10, 2025 | Volume: 29 | Issue: 8 | Pages: No page available

10.1111/petr.70222 | PMID 41208055 Get It

ABSTRACT IPTA created the SMARTER Initiative to address persistent gaps in pediatric transplant education worldwide. Through webinars, podcasts, case discussions, and interactive resources, SMARTER provides trainees and allied professionals with accessible, peer‐reviewed content across all major organ systems. The program is designed for global reach, with downloadable modules, mobile compatibility, and recorded sessions to accommodate different regions and time zones. Since its launch, SMARTER has shown strong engagement, with fellows reporting that the platform helps them prepare for board exams, improve clinical decision‐making, and connect learning directly to patient care. Survey feedback highlights high satisfaction and identifies opportunities for further growth, such as expanded case‐based modules, procedural videos, and simulation exercises. By reducing disparities in transplant training and supporting collaboration, SMARTER is positioned to strengthen existing curricula and promote a better‐prepared, more globally connected transplant workforce.
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis
Zhang, Ting , Mohindroo, Chirayu , Wang, Xiaoyu , Dutta, Diptavo , Liu, Jia , Katta, Shilpa, Li, Shengchao A. , Wang, Jiahui , Antwi, Samuel O. , Bracci, Paige M. , Du, Mengmeng, Gallinger, Steven , Goodman, Phyllis J. , Katzke, Verena, Patel, Alpa V. , Visvanathan, Kala , Andreotti, Gabriella , Brennan, Paul , Buring, Julie E. , Chanock, Stephen J., Chen, Yu , Giovannucci, Edward L. , Haiman, Christopher A. , Hassan, Manal M. , Holly, Elizabeth A., Jones, Miranda R. , Kraft, Peter, Kurtz, Robert C. , Ng, Kimmie , Oberg, Ann L. , Peters, Ulrike , Rabe, Kari G. , Rothman, Nathaniel , Sesso, Howard D. , Yuan, Chen, Wolpin, Brian M. , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Mohindroo, Chirayu , Wang, Xiaoyu , Dutta, Diptavo , Liu, Jia , Li, Shengchao A , Antwi, Samuel O , Arslan, Alan A , Beane Freeman, Laura E , Canzian, Federico , Du, Mengmeng , Goodman, Phyllis J , Katzke, Verena , Kooperberg, Charles , Marchand, Loïc Le , Neale, Rachel E , Perdomo, Sandra , Shu, Xiao-Ou , Visvanathan, Kala , Van Den Eeden, Stephen K , White, Emily E. , Zheng, Wei , Albanes, Demetrius , Andreotti, Gabriella , Brennan, Paul , Buring, Julie E , Chanock, Stephen Jacob , Chen, Yu , Darst, Burcu F , Ferrari, Pietro , Giovannucci, Edward L , Goggins, Michael G , Haiman, Christopher A , Hassan, Manal M , Hung, Rayjean J , Jones, Miranda R , Kraft, Peter , Malats, Nuria , Moore, Steven C , Ng, Kimmie , Oberg, Ann L , Orlow, Irene , Peters, Ulrike , Porta, Miquel , Chaffee, Kari G. , Sánchez, Maria-Jose , Sesso, Howard D , Southey, Melissa C , Um, Caroline Y , Yarmolinsky, James , Yu, Herbert , Yuan, Chen , Zhong, Jun , Wolpin, Brian M , Risch, Harvey A , Amundadottir, Laufey , Klein, Alison P , Yu, Kai , Zhang, Haoyu , Stolzenberg-Solomon, Rachael , Zhang, Ting , Hua, Xing , Arslan, Alan A. , Freeman, Laura E. Beane , Canzian, Federico , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Darst, Burcu F. , Goggins, Michael , Hung, Rayjean J. , Malats, Núria , Moore, Steven C. , Orlow, Irene , Porta, Miquel , Sánchez, María‐José , Silverman, Debra T. , Southey, Melissa C. , Um, Caroline Y. , Yu, Kai , Risch, Harvey A. , Ámundadóttir, Laufey T. , Klein, Alison P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 8, 2025 | Volume: 118 | Issue: 3 | Pages: 437-447

10.1093/jnci/djaf308 | PMID 41206949 Get It

Abstract Background The associations between different types of diabetes, characterized by distinct pathophysiology and genetic architecture, and pancreatic ductal adenocarcinoma (PDAC) risk are not understood. Methods We investigated associations of genetic susceptibility to type 2 diabetes (T2D), 8 T2D mechanistic clusters, type 1 diabetes (T1D), and maturity-onset diabetes of the young (MODY) with PDAC risk. We used genome-wide association study (GWAS) summary-level statistics for T2D (242 283 cases, 1 569 734 controls), T1D (18 942 cases, 501 638 controls), and PDAC (10 244 cases and 360 535 controls) in individuals of European ancestry. Results Two-sample Mendelian randomization (MR) using the Robust Adjusted Profile Score (MR-RAPS) method indicated that genetically predicted T2D was associated with PDAC risk (OR = 1.10; 95% CI = 1.05 to 1.15), particularly the T2D obesity (OR = 1.28; 95% CI = 1.15 to 1.42) and lipodystrophy (OR = 1.25; 95% CI = 1.03 to 1.51) clusters. No association was observed for T1D with PDAC risk (OR = 1.01; 95% CI = 0.99 to 1.02). Pathway/gene-set analysis using the summary-based Adaptive Rank Truncated Product (sARTP) method revealed a significant association between the MODY gene-sets and PDAC risk (P = 1.5 × 10−8), which remained after excluding 20 known PDAC GWAS loci (P = 7.6 × 10−4). HNF1A, FOXA3, and HNF4A were the top contributing genes after excluding the previously identified GWAS loci regions. Conclusions Our results from this genetic association study support that T2D, particularly the obesity and lipodystrophy mechanistic clusters, and MODY genomic susceptibility regions play a role in the etiology of PDAC.